Article thumbnail

First experience of using Brentuximab vedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature

By N.G. CHERNOVA, E.E. ZVONKOV and D.S. BADMAZHAPOVA

Abstract

Nodal anaplastic ALK-negative large cell lymphoma (nALCL, ALK-) is a Т-cell lymphoma that is characterized by aggressive clinical course and low sensitivity to СНОР (cyclophosphamide, doxorubicin, vincristine, prednisolone) and other chemotherapy regimen. In the article we present a literature review and describe our clinical case of nALCL, ALK-. For the first time a combination of Brentuximab vedotin with modified program NHL-BFM-90 was used as a first-line therapy. As a result of immunochemotherapy a complete antineoplastic effect was obtained. For consolidation of this effect high-dose chemotherapy with following autologous blood stem cell transplantation was performed. The chosen treatment tactics allowed to achieve a complete remission in a medium risk group patient

Topics: Brentuximab vedotin, anaplastic large cell lymphoma, ALK-negative, modified program NHL-BFM-90, high-dose chemotherapy, autologous blood stem cell transplantation, Medicine, R
Publisher: "Consilium Medicum" Publishing house
Year: 2018
OAI identifier: oai:doaj.org/article:e9ba462d8d304be8a6be0d343c1661cf
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://ter-arkhiv.ru/en/archiv... (external link)
  • https://doaj.org/toc/0040-3660 (external link)
  • https://doaj.org/article/e9ba4... (external link)
  • https://doaj.org/toc/2309-5342 (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.